Gubra News and Resources

AbbVie has announced a licensing agreement with Gubra to develop and commercialize GUB014295, a potential best-in-class, long-acting amylin analog for obesity treatment. The agreement marks AbbVie’s entry into the obesity market, an area of growing pharmaceutical focus. GUB014295, currently in a